hotspot -WSS

hotspot

author：hotspot 2025-09-06 01:50:41 - browse：29

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Medicare to cover more brain scans for Alzheimer’s patients

hotspot

focus

WSS

A disappointing year of Humira biosimilars

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Medicare has a new plan to address drug shortages

Medicare threatens to cut off funding for HCA's Mission hospital

Medicare Advantage proposed rates disappoint insurers

Group opposing PBM reform sets lobbying record

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Cosmetics set for new safety regulation. Why the industry is on board

United colonoscopy coverage change 'may cost lives,' doctors say

Biden report: The neurospychology of memory and aging

Sports medicine is finally prioritizing gender equality

Doctors find melanoma drugs effective against rare brain cancer

Medical leaders decry Supreme Court decision on affirmative action

Why did Pfizer dish out millions for a Super Bowl ad?

How one medical school became remarkably diverse

Readout LOUD podcast: How biotech is using artificial intelligence

explore

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

To avoid data mishandling cases, universities eye AI and other tools

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

Group opposing PBM reform sets lobbying record

Cosmetics set for new safety regulation. Why the industry is on board

Doctors find melanoma drugs effective against rare brain cancer

hotspot

focus

focus

leisure time